Обоснование применения крема пимекролимус 1% для проактивной терапии атопического дерматита у детей

Атопический дерматит (АтД) является многофакторным воспалительным заболеванием кожи с высокой распространенностью в детской популяции. Согласно актуальным клиническим руководствам и экспертным докладам, для предупреждения обострений АтД необходимо проведение длительного поддерживающего лечения. В статье обобщены результаты основных исследований крема пимекролимус 1%. Показаны его эффективность и благоприятный профиль безопасности при длительной проактивной терапии АтД у детей.

1. Maliyar K, Sibbald C, Pope E, et al. Diagnosis and Management of Atopic Dermatitis. Adv Skin Wound Care. 2018;31(12):538-550. doi: 10.1097/01.asw.0000547414.38888.8d

2. Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733-743. doi: 10.1016/s0140-6736(06)69283-0

3. Busse WW. The atopic march: Fact or folklore? Ann Allergy Asthma Immunol. 2018;120(2):116-118. doi: 10.1016/j.anai.2017.10.029

4. Kemp AS. Cost of Illness of Atopic Dermatitis in Children. Pharmacoeconomics. 2003;21(2):105-113. doi: 10.2165/00019053-200321020-00003

5. Kowalska-Olędzka E, Czarnecka M, Baran A, et al. Epidemiology of atopic dermatitis in Europe. J Drug Assess. 2019;8(1):126–128. doi: 10.1080/21556660.2019.1619570

6. Williams H, Stewart A, von Mutius E, et al. Is eczema really on the increase worldwide? J Allergy Clin Immunol. 2008;121(4):947-954. e15. doi: 10.1016/j.jaci.2007.11.004

7. Mallol J, Crane J, von Mutius E, et al. The International Study of Asthma and Allergies in Childhood (ISAAC) phase three: a global synthesis. Allergol Immunopathol (Madr). 2013;41(2):73-85. doi: 10.1016/j.aller.2012.03.001

8. David Boothe W, Tarbox JA, Tarbox MB. Atopic Dermatitis: Pathophysiology. Adv Exp Med Biol. 2017;1027:21-37. doi: 10.1007/978-3-319-64804-0_3

9. Cork MJ, Danby SG, Vasilopoulos Y, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol. 2009;129(8):1892-1908. doi: 10.1038/jid.2009.133

10. Sroka-Tomaszewska J, Trzeciak M. Molecular Mechanisms of Atopic Dermatitis Pathogenesis. Int J Mol Sci. 2021;22(8):4130. doi: 10.3390/ijms22084130

11. Brown SJ, Asai Y, Cordell HJ, et al. Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. J Allergy Clin Immunol. 2011;127(3):661-667. doi: 10.1016/j.jaci.2011.01.031

12. Marenholz I, Kerscher T, Bauerfeind A, et al. An interaction between filaggrin mutations and early food sensitization improves the prediction of childhood asthma. J Allergy Clin Immunol. 2009;123(4):911-916. doi: 10.1016/j.jaci.2009.01.051

13. Weidinger S, Illig T, Baurecht H, et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol. 2006;118(1):214-219. doi: 10.1016/j.jaci.2006.05.004

14. Matsunaga MC, Yamauchi PS. IL-4 and IL-13 Inhibition in Atopic Dermatitis. J Drugs Dermatol. 2016;15(8):925-929.

15. Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007;120(1):150-155. doi: 10.1016/j.jaci.2007.04.031

16. Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc. 2019;40(2):84-92. doi: 10.2500/aap.2019.40.4202

17. Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411-417. doi: 10.1016/j.jaci.2005.10.033

18. Meng J, Moriyama M, Feld M, et al. New mechanism underlying IL-31-induced atopic dermatitis. J Allergy Clin Immunol. 2018;141(1):1677-1689.e8. doi: 10.1016/j.jaci.2017.12.1002

19. Turner MJ, Zhou B. A new itch to scratch for TSLP. Trends Immunol. 2014;35(2):49-50. doi: 10.1016/j.it.2013.12.001

20. Yosipovitch G, Berger T, Fassett MS. Neuroimmune interactions in chronic itch of atopic dermatitis. J Eur Acad Dermatol Venereol. 2020;34(2):239-250. doi: 10.1111/jdv.15973

21. Fujii M. Current Understanding of Pathophysiological Mechanisms of Atopic Dermatitis: Interactions among Skin Barrier Dysfunction, Immune Abnormalities and Pruritus. Biol Pharm Bull. 2020;43(1):12-19. doi: 10.1248/bpb.b19-00088

22. Murota H, Katayama I. Exacerbating factors of itch in atopic dermatitis. Allergol Int. 2017;66(1):8-13. doi: 10.1016/j.alit.2016.10.005

23. Rinaldi G. The Itch-Scratch Cycle: A Review of the Mechanisms. Dermatol Pract Concept. 2019;9(2):90-97. doi: 10.5826/dpc.0902a03

24. Dharmage SC, Lowe AJ, Matheson MC, et al. Atopic dermatitis and the atopic march revisited. Allergy. 2013;69(1):17-27. doi: 10.1111/all.12268

25. Kapoor R, Menon C, Hoffstad O, et al. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J Am Acad Dermatol. 2008;58(1):68-73. doi: 10.1016/j.jaad.2007.06.041

26. Lack G. Update on risk factors for food allergy. J Allergy Clin Immunol. 2012;129(5):1187-1197. doi: 10.1016/j.jaci.2012.02.036

27. Kelleher MM, Dunn-Galvin A, Gray C, et al. Skin barrier impairment at birth predicts food allergy at 2 years of age. J Allergy Clin Immunol. 2016;137(4):1111-1116.e8. doi: 10.1016/j.jaci.2015.12.1312

28. Mullins RJ, Wainstein BK, Barnes EH, et al. Increases in anaphylaxis fatalities in Australia from 1997 to 2013. Clin Exp Allergy. 2016;46(8):1099-1110. doi: 10.1111/cea.12748

29. Wollenberg A, Christen-Zach S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717-2744. doi: 10.1111/jdv.16892

30. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850-878. doi: 10.1111/jdv.14888

31. Wollenberg A, Ehmann LM. Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol. 2012;24(3):253-260. doi: 10.5021/ad.2012.24.3.253

32. Wollenberg A, Frank R, Kroth J, Ruzicka T. Proactive therapy of atopic eczema--an evidence-based concept with a behavioral background. J Dtsch Dermatol Ges. 2009;7(2):117-121. doi: 10.1111/j.1610-0387.2008.06772.x

33. Macheleidt O, Kaiser HW, Sandhoff K. Deficiency of epidermal proteinbound omega-hydroxyceramides in atopic dermatitis. J Invest Dermatol. 2002;119(1):166-173. doi: 10.1046/j.1523-1747.2002.01833.x

34. Wollenberg A, Rawer HC, Schauber J. Innate immunity in atopic dermatitis. Clin Rev Allergy Immunol. 2011;41(3):272-281. doi: 10.1007/s12016-010-8227-x

35. Arakawa H, Shimojo N, Katoh N, et al. Consensus statements on pediatric atopic dermatitis from dermatology and pediatrics practitioners in Japan: Goals of treatment and topical therapy. Allergol Int. 2020;69(1):84-90. doi: 10.1016/j.alit.2019.08.006

36. Wollenberg A, Bieber T. Proactive therapy of atopic dermatitis — an emerging concept. Allergy. 2009;64(2):276-278. doi: 10.1111/j.1398-9995.2008.01803.x

37. Peserico A, Stadtler G, Sebastian M, et al. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol. 2008;158(4):801-807. doi: 10.1111/j.1365-2133.2008.08436.x

38. Wollenberg A, Reitamo S, Atzori F, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy. 2008;63(7):742-750.

39. Carr WW. Topical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations. Paediatr Drugs. 2013;15(4):303-310. doi: 10.1007/s40272-013-0013-9

40. Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26(8):1045-1060. doi: 10.1111/j.1468-3083.2012.04635.x

41. Garrott HM, Walland MJ. Glaucoma from topical corticosteroids to the eyelids. Clin Exp Ophthalmol. 2004;32(2):224-226. doi: 10.1111/j.1442-9071.2004.00787.x

42. Gschwind H-P, Waldmeier F, Zollinger M, et al. Pimecrolimus: Skin disposition after topical administration in minipigs in vivo and in human skin in vitro. Eur J Pharm Sci. 2008;33(1):9-19. doi: 10.1016/j.ejps.2007.09.004

43. Weiss HM, Fresneau M, Moenius T, et al. Binding of pimecroli-mus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application. Drug Metab Dispos. 2008;36(9):1812-1818. doi: 10.1124/dmd.108.021915

44. Aubert-Wastiaux H, Moret L, Le Rhun A, et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol. 2011;165(4):808-814. doi: 10.1111/j.1365-2133.2011.10449.x

45. Gutfreund K, Bienias W, Szewczyk A, KaszubaA. Topical calcineu-rin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use. Postepy Dermatol Alergol. 2013;30(3):165-169. doi: 10.5114/pdia.2013.35619

46. Hoetzenecker W, Meingassner JG, Ecker R, et al. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol. 2004;122(3):673-684. doi: 10.1111/j.0022-202X.2004.22324.x

47. Sambyal K, Singh RV. Bioprocess and genetic engineering aspects of ascomycin production: a review. J Genet Eng Biotechnol. 2020;18(1):73. doi: 10.1186/s43141-020-00092-0

48. Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, doubleblind controlled study. Br J Dermatol. 2001;144(3):507-513. doi: 10.1046/j.1365-2133.2001.04076.x

49. Murrell DF, Calvieri S, Ortonne JP, et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol. 2007;157(5):954-959. doi: 10.1111/j.1365-2133.2007.08192.x

50. Grzanka A, Zebracka-Gala J, Rachowska R, et al. The effect of pimecrolimus on expression of genes associated with skin barrier dysfunction in atopic dermatitis skin lesions. Exp Dermatol. 2012;21:184-188. doi: 10.1111/j.1600-0625.2011.01417.x

51. Jensen JM, Pfeiffer S, Witt M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol. 2009;123(5):1124-1133. doi: 10.1016/j.jaci.2009.03.032

52. Luger T, De Raeve L, Gelmetti C, et al. Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm. Eur J Dermatol. 2013;23(6):758-766. doi: 10.1684/ejd.2013.2169

53. Stander S, Schurmeyer-Horst F, Luger TA, Weisshaar E. Treatment of pruritic diseases with topical calcineurin inhibitors. Ther Clin Risk Manag. 2006;2(2):213-218. doi: 10.2147/tcrm.2006.2.2.213

54. Stander S, Stander H, Seeliger S, et al. Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin. Br J Dermatol. 2007;156(5):1020-1026. doi: 10.1111/j.1365-2133.2007.07813.x

55. Luger T, Paller AS, Irvine AD, et al. Topical therapy of atopic dermatitis with a focus on pimecrolimus. J Eur Acad Dermatol Venereol. 2021;35(7):1505-1518. doi: 10.1111/jdv.17272

56. Sher LG, Chang J, Patel IB, et al. Relieving the pruritus of atopic dermatitis: a meta-analysis. Acta Derm Venereol. 2012;92(5):455-461. doi: 10.2340/00015555-1360

57. Kaufmann R, Bieber T, Helgesen AL, et al. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. Allergy. 2006;61(3):375-381. doi: 10.1111/j.1398-9995.2005.00977.x

58. Sigurgeirsson B, Boznanski A, Todd G, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015;135(4):597-606. doi: 10.1542/peds.2014-1990

59. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecro-limus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110(1 Pt 1):e2. doi: 10.1542/peds.110.1.e2

60. Мурашкин Н.Н., Макарова С.Г., Григорьев С.Г. и др. Профилактика развития транскутанной сенсибилизации к белкам коровьего молока при атопическом дерматите у детей первого года жизни: когортное исследование // Вопросы современной педиатрии. — 2020. — Т. 19. — № 6. — С. 538-544. doi: 10.15690/vsp.v19i6.2152

61. Федоров Д.В., Мурашкин Н.Н., Макарова С.Г., Иванов Р.А. Стратегии выбора терапевтической тактики снижения риска развития транскутанной сенсибилизации у детей первого года жизни, страдающих атопическим дерматитом: когортное ретроспективно-проспективное исследование // Педиатрическая фармакология. — 2021. — Т. 18. — № 1. — С. 8-16. doi: 10.15690/pf.v18i1.2219

62. Paul C, Cork M, Rossi AB, et al. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics. 2006;117(1):e118-e128. doi: 10.1542/peds.2005-1188

63. Papp KA, Breuer K, Meurer M, et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol. 2005;52(2):247-253. doi: 10.1016/j.jaad.2004.08.046

64. Papp KA, Werfel T, Folster-Holst R, et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol. 2005;52(2):240-246. doi: 10.1016/j.jaad.2004.09.016

65. Lubbe J, Friedlander SF, Cribier B, et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol. 2006;7(2):121-131. doi: 10.2165/00128071-200607020-00005

66. Legendre L, Barnetche T, Mazereeuw-Hautier J, et al. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: a systematic review and meta-analysis. J Am Acad Dermatol. 2015;72(6):992-1002. doi: 10.1016/j.jaad.2015.02.1116

67. Paller AS, Folster-Holst R, Chen SC, et al. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol. 2020;83(2):375-381. doi: 10.1016/j.jaad.2020.03.075

68. Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol. 2004;51(4):515-525. doi: 10.1016/j.jaad.2004.01.051

69. Reda AM, Elgendi A, Ebraheem AI, et al. A practical algorithm for topical treatment of atopic dermatitis in the Middle East emphasizing the importance of sensitive skin areas. J Dermatol Treat. 2019;30(4):366-373. doi: 10.1080/09546634.2018.1524823

70. Мурашкин Н.Н., Епишев Р.В., Фёдоров Д.В. и др. Синдром чувствительной кожи при атопическом дерматите у детей: особенности патогенеза и терапевтической тактики // Вопросы современной педиатрии. — 2019. — Т. 18. — № 4. — С. 285293. doi: 10.15690/vsp.v18i4.2046